Hematopoietic Stem Cell Transplantation (Immunology) - Drugs in Development, 2021
Summary Hematopoietic Stem Cell Transplantation (Immunology) - Drugs in Development, 2021 provides an overview of the Hematopoietic Stem Cell Transplantation pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Hematopoietic Stem Cell Transplantation, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hematopoietic Stem Cell Transplantation and features dormant and discontinued projects.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope - The report provides a snapshot of the Global Therapeutic Landscape of Hematopoietic Stem Cell Transplantation (Immunology). - The report reviews pipeline therapeutics for Hematopoietic Stem Cell Transplantation (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The report covers pipeline products based on various stages of development ranging from discovery till pre-registration. - The report features descriptive drug profiles for the pipeline products which includes, Product Description, Descriptive MoA, R&D Brief, Licensing and Collaboration details & Other Developmental Activities. - The report reviews key players involved in the development of Hematopoietic Stem Cell Transplantation (Immunology) therapeutics and enlists all their major and minor projects. - The report assesses Hematopoietic Stem Cell Transplantation (Immunology) therapeutics based on Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. - The report summarizes all the dormant and discontinued pipeline projects. - The report reviews latest news related to pipeline therapeutics for Hematopoietic Stem Cell Transplantation (Immunology).
Reasons to Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective Research and Development (R&D) strategies. - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Identify and understand important and diverse types of therapeutics under development for Hematopoietic Stem Cell Transplantation (Immunology). - Identify potential new clients or partners in the target demographic. - Develop strategic initiatives by understanding the focus areas of leading companies. - Plan Mergers and Acquisitions (M&A) effectively by identifying key players and it’s most promising pipeline therapeutics. - Devise corrective measures for pipeline projects by understanding Hematopoietic Stem Cell Transplantation (Immunology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Our reports have been used by over 10K customers, including:
Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) - Drugs in Development, 2021 Summary According to the recently published report ’Insulin Like Growth Factor I - Drugs In Development, 2021’; Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1)...
Masked Antibodies & Cytokines As Prodrugs: a landscape analysis of stakeholders, technologies, pipelines, business and financing from an industry perspective This report provides you with a landscape description and analysis of prodrug antibodies and cytokines employing conventional and novel masking technology...
The global biosimilars market is projected to reach USD 44.7 billion by 2026 from USD 15.6 billion in 2021, at a CAGR of 23.5% during the forecast period of 2021 to 2026. Market growth is largely driven by the rising incidence of chronic diseases and increasing demand of biosimilars for their cost-effectiveness. Regulatory approvals and other...
The Global Filgrastim Market size is expected to reach $953.4 million by 2027, rising at a market growth of 8.0% CAGR during the forecast period. Filgrastim refers to the recombinant DNA-derived granulocyte colony-stimulating factor (G-CSF), which is generally utilized to cure low blood neutrophils. It is especially used in cases wherein...
The Global Biologics CDMO Market was valued at USD 9.93 billion in 2020 and is expected to reach USD 18.63 billion by 2026, registering a CAGR of 10.87% during the forecast period (2021-2026). The CMO/CDMO service sector is uniquely positioned to address some of the challenges that drug developers are facing amid the COVID-19 pandemic....
The global single-use bioreactors market is projected to reach USD 8.8 billion by 2026 from USD 3.4 billion in 2021, at a CAGR of 21.1% during the forecast period. Increasing adoption of SUBs among small companies and startups, reduced automation complexity, ease in the cultivation of marine organisms, reduced energy and water consumption,...
The Formulation Development Outsourcing market was valued at approximately USD 8,055 million in 2020 and is expected to witness a revenue of USD 12,650 million in 2026, with a CAGR of 7.2% over the forecast period. The rapidly evolving threat of COVID-19 is impacting lives, communities, businesses, and industries around the world. The...
“Axial spondyloarthritis - Pipeline Insight, 2021,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Axial spondyloarthritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.